Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-α-positive breast tumor cells through multiple molecular cross-talks

被引:38
|
作者
Banerjee, S
Sengupta, K
Saxena, NK
Dhar, K
Banerjee, SK
机构
[1] Vet Adm Med Ctr, Div Res 151, Canc Res Unit, Kansas City, MO 64128 USA
[2] Univ Kansas, Med Ctr, Dept Med, Div Hematol & Oncol, Kansas City, KS 66103 USA
关键词
D O I
10.1158/1541-7786.MCR-04-0130
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidermal growth factor (EGF) is a mitogen for estrogen receptor (ER)-positive breast tumor cells, and it has been proven that EGF occasionally mimicked estrogen action and cross-talks with ER-alpha to exert its activity. Therefore, the present study was undertaken to explore whether EGF is able to modulate the expression of Wnt-1-induced signaling protein-2/connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed 5 (WISP-2/CCN5), an estrogen-responsive gene, in normal and transformed cell lines of the human breast and, if so, whether this induction is critical for EGF mitogenesis and what downstream signaling pathways are associated with this event. Here, we show that EGF-induced WISP-2 expression in ER- and EGF receptor-positive noninvasive MCF-7 breast tumor cells was dose and time dependent and that expression was modulated at transcription level. A synergism was seen in combination with estrogen. Moreover, small interfering RNA-mediated inhibition of WISP-2/CCN5 activity in MCF-7 cells resulted in abrogation of proliferation by EGF. The multiple molecular cross-talks, including the interactions between phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways and two diverse receptors (i.e., ER-alpha and EGFR), were essential in the event of EGF-induced WISP-2/CCN5 up-regulation in MCF-7 cells. Moreover, EGF action on WISP-2/CCN5 is restricted to ER- and EGFR-positive noninvasive breast tumor cells, and this effect of EGF cannot be instigated in ER-alpha-negative and EGFR-positive normal or invasive breast tumor cells by introducing ER-alpha. Finally, regulation of phosphorylation of ER-alpha and EGFR may play critical roles in EGF-induced transcriptional activation of WISP-2 gene in breast tumor cells.
引用
收藏
页码:151 / 162
页数:12
相关论文
共 50 条
  • [21] Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer
    Honda, Chikako
    Kurozumi, Sasagu
    Katayama, Ayaka
    Hanna-Khalil, Bishoy
    Masuda, Kei
    Nakazawa, Yuko
    Ogino, Misato
    Obayashi, Sayaka
    Yajima, Reina
    Makiguchi, Takaya
    Oyama, Tetsunari
    Horiguchi, Jun
    Shirabe, Ken
    Fujii, Takaaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (06)
  • [22] Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal status
    Yamashita, Hiroko
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (06): : 220 - 224
  • [23] Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer
    Tomiguchi, Mai
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Goto-Yamaguchi, Lisa
    Fujiki, Yoshitaka
    Fujiwara, Saori
    Sueta, Aiko
    Hayashi, Mitsuhiro
    Takeshita, Takashi
    Inao, Touko
    Iwase, Hirotaka
    CANCER SCIENCE, 2016, 107 (04) : 491 - 498
  • [24] ERBB-2 EXPRESSION IN ESTROGEN-RECEPTOR-POSITIVE BREAST-TUMOR CELLS IS REGULATED BY GROWTH-MODULATORY REAGENTS
    TAVERNA, D
    ANTONIOTTI, S
    MAGGIORA, P
    DATI, C
    DEBORTOLI, M
    HYNES, NE
    INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (04) : 522 - 528
  • [25] Induction of transforming growth factor-β receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2′-deoxycytidine
    Ammanamanchi, S
    Kim, SJ
    Sun, LZ
    Brattain, MG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (26) : 16527 - 16534
  • [26] Prognostic significance of the primary tumor site and immune indexes in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
    Song, Xinming
    Ma, Jianli
    Zhang, Han
    Zhang, Qingyuan
    GLAND SURGERY, 2020, 9 (05) : 1450 - 1468
  • [27] Heterogeneity of tumor immune microenvironment to predict everolimus efficacy in premenopausal women with hormone receptor- positive/human epidermal growth factor receptor 2-negative adavanced breast cancer
    Tan, Yujing
    Ma, Fei
    Wang, Jiayu
    Zhang, Pin
    Xu, Binghe
    Xue, Liyan
    Fan, Ying
    CANCER RESEARCH, 2024, 84 (09)
  • [28] Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes
    Harlozinska, A
    Bar, JK
    Wenderski, R
    Bebenek, M
    IN VIVO, 1996, 10 (02): : 217 - 222
  • [29] Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells
    Long, Jaclyn S.
    Edwards, Joanne
    Watson, Carol
    Tovey, Sian
    Mair, Kirsty M.
    Schiff, Rachel
    Natarajan, Viswanathan
    Pyne, Nigel J.
    Pyne, Susan
    MOLECULAR AND CELLULAR BIOLOGY, 2010, 30 (15) : 3827 - 3841
  • [30] Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer
    Miyoshi, Yuichiro
    Shien, Tadahiko
    Ogiya, Akiko
    Ishida, Naoko
    Yamazaki, Kieko
    Horii, Rie
    Horimoto, Yoshiya
    Masuda, Norikazu
    Yasojima, Hiroyuki
    Inao, Touko
    Osako, Tomofumi
    Takahashi, Masato
    Tomioka, Nobumoto
    Wanifuchi-Endo, Yumi
    Hosoda, Mitsuchika
    Doihara, Hiroyoshi
    Yamashita, Hiroko
    ONCOLOGY LETTERS, 2019, 17 (02) : 2177 - 2186